At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 32 enrolled
Drug / intervention
Pyrimethaminedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase I/II Study of SOD1 Inhibition by Pyrimethamine in Familial ALS
In Brief
A Phase 2 clinical trial evaluating Pyrimethamine for Familial Amyotrophic Lateral Sclerosis. Completed, enrolled 32 participants across 5 sites in 4 countries.
Detailed Summary
The objective of this study will be to evaluate the safety, tolerability and effect on SOD1 levels by pyrimethamine in patients with familial amyotrophic lateral sclerosis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsFamilial Amyotrophic Lateral Sclerosis
CountriesGermany, Italy, Sweden, United States
CollaboratorsMuscular Dystrophy Association
Timeline
Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartNov 2009
First PostedMar 2010
Primary CompletionDec 2014
Study CompletionMay 2016
TodayJul 2026
First PostedMar 10, 2010
Enrollment StartNov 1, 2009
Primary CompletionDec 1, 2014
Study CompletionMay 1, 2016
TodayJul 2, 2026
Enrollment to primary: 5.1 yearsPosted 16.3 years ago
Interventions
Pyrimethaminedrug
Open Label, dose escalating,